Latest Industry Insights

Technology Networks recently spoke with Paul Brennan, President and CEO at NervGen Pharma, to gain his insights on why previous attempts to treat Alzheimer's disease have failed, how the novel technology platform NVG-291 works and what promise it holds for AD.

Variability in the quality of raw materials can not only impact production yields, but can also affect the quality, efficacy and safety of the final pharmaceutical product. In this interview, learn about how the capabilities of two handheld analyzers ensure reliable material identity verification.

Many clinical trials fail due to lack of efficacy. But while some of this may be due to poor target selection during the drug discovery process, it’s becoming increasingly clear that only certain patients respond to treatments. So how exactly does precision medicine increase the likelihood of success in clinical trials?

Martin and Tom discuss the evolution of drug discovery, the challenges faced by those working in the field, and share how AI, machine learning and robotics are impacting the discovery and clinical success of drugs.

A typical drug compound library can easily be comprised of millions of compounds – managing, processing and analyzing these libraries takes both time and effort, as well as being costly. But what if it was possible to screen vast libraries in days, rather than weeks, or even months?

We recently spoke with Thermo Fisher Scientific's Eric Grumbach, to learn more about the opening of the company's new Pharma and BioPharma Center, located in Shanghai, China. The center is set to support the rapid delivery of novel and high-quality therapeutics by providing expertise in critical analytical techniques and specialized workflows.

Technology Networks recently spoke with Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer at Kaleido Biosciences, to learn more about the development of Microbiome Metabolic Therapies (MMTs), and how Kaleido are advancing a pipeline of MMTs for a variety of disease indications.

Geraldine A. Hamilton, PhD, President and Chief Scientific Officer of Emulate Inc., shares her perspectives on the challenges of using animal toxicity models and discusses how these can translate to late-stage attrition in drug development. She also highlights the advantages of using “organ-on-chip” technologies for toxicity testing and delves into the company’s recent findings related to the ability to reproduce human and cross-species drug toxicities using a liver-chip

With constant conversations examining the potential of CRISPR technology, it can be hard to focus on what has been achieved since 2012 and to look toward the future to determine what may be achievable both in the near – and longer – term.

Ubiquigent's Jason Brown and Jason Mundin discuss the role of the ubiquitin cascade in cellular signaling and explain how it can be exploited to support protein degradation-focused drug discovery.